key: cord-0729537-nu51pn3s
authors: Matias-Guiu, Jorge; Matias-Guiu, Jordi A.; Garrido, Carmen; Pimienta, Genaro; Reyes, Patricio F.; Baig, Abdul Mannan; Gomez-Pinedo, Ulises
title: Editorial: COVID-19 in CNS and PNS: Basic and Clinical Focus on the Mechanisms of Infection and New Tools for the Therapeutic Approach
date: 2022-03-03
journal: Front Neurol
DOI: 10.3389/fneur.2022.838227
sha: 0527455215b7ce5d43fb183a8dce78039ad33415
doc_id: 729537
cord_uid: nu51pn3s

nan

The COVID-19 pandemic has had significant implications not only for health but also for lifestyles and for organizations both in the healthcare sector and in other spheres. Before December 2019, other coronaviruses had been described that had presented endemically and in some cases caused epidemics, but none spread to such an extent globally; the COVID-19 pandemic is reminiscent of other historic epidemics such as the influenza epidemic of the last century, whose sequelae, including neurological symptoms, were felt for decades (1) . Of the other coronaviruses (CoV) affecting humans, 2 are classified as αCoV (HCoV-229E and HKU-NL63) and 4 as βCoV (HCoV-OC43, HCoV-HKU1, SARS-CoV, and MERS-CoV). SARS-CoV and MERS-CoV caused severe infections both in healthy individuals and in people with immune deficiencies, and were associated with high mortality rates, whereas the others are associated with seasonal outbreaks of flu-like symptoms with relatively limited capacity for transmission. However, all of these viruses have either been associated with neurological symptoms or been detected in biological samples taken from the central nervous system (CNS) (2, 3). On 31 December 2019, the World Health Organization reported a novel CoV (SARS-CoV-2) in patients with pneumonia in the city of Wuhan, in the Chinese province of Hubei, which spread rapidly through the rest of the world. The novel virus is a βCoV and bears considerable similarity to SARS-CoV. The main structural differences between SARS-CoV and SARS-CoV-2 are observed in the fusion protein and in accessory proteins, particularly ORF3b and ORF8. As is the case with SARS-CoV, subunit 1 of the novel coronavirus fusion protein also binds to the ACE2 receptor, hence the name SARS-CoV-2 (4). It has been suggested since early in the pandemic that the virus may have direct and indirect effects on the CNS (5), with many researchers and authors beginning to analyze a pandemic with worldwide effects; an enormous amount of information has been generated, largely due to the scientific community's desire for progress. However, much of this information is from case reports, anecdotal series, and many speculative articles based more on opinion than experimentation (6) . Despite the great efforts to generate evidence to enable advances in our understanding of the virus and associated disease, much speculation remains today with regard to the evidence. Such aspects as its epidemiology, transmission factors, and the impact of mass vaccination are conditioned by data from studies that present considerable bias (7) and are not evidence-based.

Since the beginning of the pandemic, there has been debate as to whether SARS-CoV-2 is able to enter the CNS and cause neurological symptoms, trigger or promote pre-existing neurological disease, or remain latent in the brain, making the organ a viral reservoir (5) . The study of the potential routes by which the virus enters the CNS (i.e., the hematogenous route or the neuronal route), facilitating this penetration, also constitute an interesting area of research (8, 9) analyzing whether the virus accesses the CNS by infecting endothelial or epithelial cells of the blood-brain barrier; by dissemination from nearby areas; or by axonal transport after infecting neurons in the peripheral nervous system. Another subject of debate is the frequency of neurological symptoms associated with the acute infection (10, 11) and their association with the CNS (12), and associated neurological disorders such as stroke (13, 14) and neuromuscular involvement (15) . Furthermore, there is an interesting debate as to whether the virus can trigger neurological disease, for example neurodegenerative disease, in the long term (it has been suggested that the infection may increase the risk of Parkinson's disease or Alzheimer's disease), and by which mechanisms (16, 17) , and whether it may facilitate age-related transcriptome or molecular changes (18) . Finally, there is controversy regarding the so-called persistent COVID-19 or post-COVID-19 syndrome, referring to symptoms persisting for 3 months after the acute infection, with particular emphasis on cognitive symptoms (19) . A recent Delphi consensus study conducted by the World Health Organization establishes 3 major criteria for diagnosing post-COVID-19 condition, 2 of which are based on the presence of neurological symptoms: fatigue and cognitive alterations (20) .

The special issue "COVID-19 in CNS and PNS: Basic and Clinical Focus on the Mechanism of Infection and New Tools for the Therapeutic Approach" includes valuable articles addressing these debates, contributing evidence to expand our understanding of the disease and its impact on the CNS. 

It remains to be determined whether the virus or its RNA can remain within structures of the CNS or whether it may remain latent or cause disease in the long term; therefore, there is a clear need for necropsy studies (21, 22) . It also seems important to identify any areas of the CNS that may present greater vulnerability to infection (though the hippocampus and basal ganglia have been suggested), whether some CNS cells present greater susceptibility to viral structures, and whether the virus or its RNA may be transported by such cell substructures as vesicles or exosomes. It is also unclear whether existing lesions, such as demyelinating plaques in multiple sclerosis, may facilitate the entry of the virus and serve as viral reservoirs. The impact of different types of vaccine on viral invasion of the CNS is another area where further study is needed. The effects of SARS-CoV-2 on the brain constitute a new challenge for neuroscientific research (23) , in which we may only advance with the greatest possible quantity of information, like that included in this special issue.

The Spanish 1918 flu and the COVID-19 disease: the art of remembering and foreshadowing pandemics

Neuroinvasion by human respiratory coronaviruses

Possible central nervous system infection by SARS coronavirus

Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan

Should we expect neurological symptoms in the SARS-CoV-2 epidemic?

The role of scientific journal editors during the COVID-19 pandemic

Prediction models for diagnosis and prognosis of covid-19: systematic review and critical appraisal

COVID-19-Associated neurological disorders: the potential route of CNS invasion and blood-brain relevance

Evidence of the COVID-19 virus targeting the CNS: tissue distribution, host-virus interaction, and proposed neurotropic mechanisms

Spectrum of headaches associated with SARS-CoV-2 infection: study of healthcare professionals

Olfactory and gustatory dysfunctions due to the coronavirus disease (COVID-19): a review of current evidence

Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19

Stroke as a complication and prognostic factor of COVID-19

Stroke in patients with COVID-19: clinical and neuroimaging characteristics

Neuromuscular presentations in patients with COVID-19

Is the brain a reservoir organ for SARS-CoV2?

SARS-CoV-2 as a potential trigger of neurodegenerative diseases

Severe COVID-19 induces molecular signatures of aging in the human brain

Brain Fog" by COVID-19 or Alzheimer's disease? a case report

Clinical Case Definition of Post COVID-19 Condition by a Delphi Consensus

What can we learn from brain autopsies in COVID-19?

Neuropathology of patients with COVID-19 in Germany: a post-mortem case series

Neurological consequences of COVID-19 and brain related pathogenic mechanisms: a new challenge for neuroscience

JM-G, UG-P, JAM-G, CG, GP, PR, and AB concept, evaluation, writing, and revision. All authors contributed to the article and approved the submitted version.

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.Copyright © 2022 Matias-Guiu, Matias-Guiu, Garrido, Pimienta, Reyes, Baig and Gomez-Pinedo. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.